Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Error in Results

Error in Results Letters Funding/Support: This article was supported by the Richard N. and Marilyn K. Figure. Possible Association of the Eyelid Manifestations Witham Professorship. to TNF-α Inhibitor Treatment Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of Initial presentation the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patient for granting permission to publish this information. 1. Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors: state of knowledge. Arch Med Sci. 2014;10(6):1175-1185. doi:10.5114/aoms.2014.47827 2. Iervolino A. EvaluatePharma world preview 2017, outlook to 2022 10th Ed. http://www.evaluategroup.com/public/reports/EvaluatePharma-World- Preview-2017.aspx. Published June 2017. Accessed February 3, 2018. 3. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthalmic Plast Reconstr Surg. 2007;23(1):63-65. doi:10.1097/IOP. 0b013e31802d97f0 Resolution after treatment discontinuation 4. Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120-122. doi:10.1016/j.ajoc. 2017.06.017 5. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13(1):15-19. doi:10.1016/j.autrev.2013.06.005 CORRECTION Data Errors in Abstract and Results: http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Error in Results

JAMA Ophthalmology , Volume 137 (2) – Feb 27, 2019

Error in Results

Abstract

Letters Funding/Support: This article was supported by the Richard N. and Marilyn K. Figure. Possible Association of the Eyelid Manifestations Witham Professorship. to TNF-α Inhibitor Treatment Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of Initial presentation the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication....
Loading next page...
 
/lp/american-medical-association/error-in-results-mhWkO3lSgt

References (1)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2018.6555
Publisher site
See Article on Publisher Site

Abstract

Letters Funding/Support: This article was supported by the Richard N. and Marilyn K. Figure. Possible Association of the Eyelid Manifestations Witham Professorship. to TNF-α Inhibitor Treatment Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of Initial presentation the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patient for granting permission to publish this information. 1. Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors: state of knowledge. Arch Med Sci. 2014;10(6):1175-1185. doi:10.5114/aoms.2014.47827 2. Iervolino A. EvaluatePharma world preview 2017, outlook to 2022 10th Ed. http://www.evaluategroup.com/public/reports/EvaluatePharma-World- Preview-2017.aspx. Published June 2017. Accessed February 3, 2018. 3. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthalmic Plast Reconstr Surg. 2007;23(1):63-65. doi:10.1097/IOP. 0b013e31802d97f0 Resolution after treatment discontinuation 4. Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120-122. doi:10.1016/j.ajoc. 2017.06.017 5. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13(1):15-19. doi:10.1016/j.autrev.2013.06.005 CORRECTION Data Errors in Abstract and Results:

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Feb 27, 2019

There are no references for this article.